{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:39:12Z","timestamp":1792841952683,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.brachy.2026.05.008","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:23:51Z","timestamp":1784114631000},"page":"935-939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of real-time TRUS-guided HDR brachytherapy monotherapy for low and favorable intermediate-risk prostate cancer and predictive value of PSA nadir"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5803-1108","authenticated-orcid":false,"given":"Miren","family":"Gazta\u00f1aga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2223-3836","authenticated-orcid":false,"given":"Javier","family":"de Areba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Flavio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Galante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Serrano-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Gonzalo","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2026.05.008_bib0001","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.05.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110381","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 gy or two fractions of 13.5 gy: a 9-year update","volume":"198","author":"Hudson","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.05.008_bib0003","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ijrobp.2008.12.067","article-title":"Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality","volume":"75","author":"Zelefsky","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.05.008_bib0004","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.05.008_bib0005","first-page":"434","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for prostate cancer: clinical outcomes and dosimetric analysis","volume":"15","author":"Prada","year":"2016","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.brachy.2026.05.008_bib0006","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.brachy.2024.10.014","article-title":"High-dose-rate (2 fractions of 13.5 Gy) and low-dose-rate brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir prostate-specific antigen","volume":"24","author":"Rodr\u00edguez Villalba","year":"2025","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2026.05.008_bib0007","doi-asserted-by":"crossref","first-page":"109807","DOI":"10.1016\/j.radonc.2023.109807","article-title":"Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer","volume":"186","author":"Nagore","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.05.008_bib0008","first-page":"1234","article-title":"High-dose-rate brachytherapy for prostate cancer: long-term clinical outcomes","volume":"20","author":"G\u00f3mez-Iturriaga","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.brachy.2026.05.008_bib0009","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3390\/cancers17193151","article-title":"Seven-year PSA \u22640.2 ng\/mL after high-dose-rate brachytherapy indicates eligibility for discontinuing PSA surveillance in prostate cancer","volume":"17","author":"Makino","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472126000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472126000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:33:50Z","timestamp":1792841630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472126000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538472126000784"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2026.05.008","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of real-time TRUS-guided HDR brachytherapy monotherapy for low and favorable intermediate-risk prostate cancer and predictive value of PSA nadir","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2026.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}